Pesquisar
CervoMed Inc
CRVOAdicionar à lista de desejos
3.690USD
+0.590+19.03%
Fechamento 07/01, 16:00（ET）Cotações atrasadas em 15 min
34.16MValor de mercado
PerdaP/L TTM
Mais detalhes de CervoMed Inc Empresa
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Informações de CervoMed Inc
Código da empresaCRVO
Nome da EmpresaCervoMed Inc
Data de listagemNov 09, 2016
CEOAlam (John J)
Número de funcionários15
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 09
Endereço20 Park Plaza, Suite 424
CidadeBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02116
Telefone16177444400
Sitehttps://cervomed.com/
Código da empresaCRVO
Data de listagemNov 09, 2016
CEOAlam (John J)
Executivos da empresa CervoMed Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.01M
+47.47%
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
785.55K
+4.11%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Dr. Sylvie L. Gregoire, Pharm.D.
Dr. Sylvie L. Gregoire, Pharm.D.
Director
Director
--
--
Dr. Marwan Noel Sabbagh, M.D.
Dr. Marwan Noel Sabbagh, M.D.
Independent Director
Independent Director
--
--
Mr. Frank E. Zavrl
Mr. Frank E. Zavrl
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.01M
+47.47%
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
785.55K
+4.11%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de CervoMed Inc?
Os cinco principais acionistas de CervoMed Inc são: Dr. Joshua S. Boger, Ph.D.
Quantas instituições possuem ações da CervoMed Inc (CRVO)?
Em 2026Q1, 130 instituições possuíam ações da CervoMed Inc, com valor de mercado aproximado de 1.35M, representando 14.61% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -2926415.00.